AbbVie (ABBV) Set To Report Q2 Earnings: What To Expect
Zacks Investment Research | Jul 22, 2019 11:58PM ET
AbbVie (NYSE:ABBV) is set to release its Q2 earnings before market open on Friday. AbbVie stock has performed very poorly YTD, falling 26%.
Overview
AbbVie Inc. is an American biopharmaceutical company based in Illinois. AbbVie was established as a spin-off of Abbott Laboratories (NYSE:ABT) in 2013. AbbVie is the marketer and producer of Humira, the best-selling drug in the world. Humira is used to treat rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and other issues related to these diseases.
AbbVie has also made a couple of acquisitions over the past couple of months. In June, AbbVie acquired Botox-producer Allergan (NYSE:AGN) plc for $63 billion. In July, AbbVie announced it would acquire Mavupharma, which would help bolster the company’s cancer drug pipeline.
Since the Allergan acquisition announcement, ABBV stock has fallen 13%. Currently, AbbVie shares are trading at 7.39 times earnings, which may make the stock seem undervalued compared to its industry’s average P/E of 14.37. However, ABBV’s lower P/E is most likely due to its falling stock price in recent months and may not be a good representation of the stock’s value.
Additionally, AbbVie is a solid dividend stock. Since November 2017, AbbVie has increased its dividend three times, the most recent being an 11% increase that came in February 2019. The annual dividend is currently at $4.28, which amounts to a dividend yield of about 6.2%.
Q2 Outlook & Earnings Trends
Revenues for Q2 are expected to fall 2% year-over-year from $8.28 billion to $8.10 billion, according to our Zacks Consensus Estimates. After years of year-over-year revenue growth, predictions suggest this will be the second quarter in a row of shrinking revenues.
In Q1, revenues fell 1.3% from Q1 2018. The primary source of the revenue decline was a decrease in international sales. International sales of Humira declined by nearly half a billion dollars, or over 25%. Humira accounts for over 50% of AbbVie’s revenue, so investors are clearly worried about the firm’s overreliance on the drug.
Get The News You Want
Our Zacks Key Company Metrics predict international Humira sales will slip by a similar amount again for Q2. While U.S. sales are expected to increase slightly, from $3.521 billion in Q2 2018 to $3.785 billion. But this growth is simply not enough to make up for the expected international revenue decrease from $1.664 billion to $1.028 billion. The decrease in international Humira sales is a result of competition in Europe.
Meanwhile, AbbVie’s earnings are expected to grow by 10.5%. The quarterly growth will help contribute to an expected fiscal 2019 growth of 11.5%, which would give fiscal EPS of $8.82 compared to $7.91 in 2018.
Bottom Line
Humira’s patent in the U.S. expired in 2016, but domestic competitors are not expected to hit the market until 2023 due to AbbVie’s strong and persistent litigation leading up to the patent expiration. Until then, AbbVie needs to continue to grow its portfolio and the addition of Botox was a big one as it can help make up for some of the revenue that will be lost to Humira competitors. The firm’s international competitors have already taken a large toll on AbbVie’s revenue. And the arrival of domestic competitors will most likely have an even more significant impact on the company.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.